Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

• Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform
• Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies
• Appointment comes as Commit looks to progress towards drug candidate (DC) nomination in cancer and autoimmune disease in 2025

Aarhus, Denmark, 8 January 2025 - Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors.

Dr Schuurman is a widely recognized scientific leader with over 25 years’ experience in antibody research, discovery, and development. She is the co-inventor of several FDA approved drugs, including amivantamab (RYBREVANT® Janssen) and epcoritamab (EPKINLY® Genmab/Abbvie).

Dr Schuurman also played a key role in the development of antibody platform technologies while at Genmab, such as DuoBody® and HexaBody®, and rose to become Senior Vice President, Head of Antibody Research and Development. A renowned speaker at scientific conferences, Dr Schuurman is currently President of The Antibody Society, a highly regarded non-profit supporting antibody-related research and development.

Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: “Janine brings a wealth of knowledge and experience that will greatly benefit Commit - both in terms of the science of antibody research and development, and in the practical know-how of building teams, pipelines and partnerships that is so essential to achieving drug approvals success. Her experience in developing meaningful therapeutic antibodies and antibody platforms will be invaluable. We look forward to partnering with her and the board to advance Commit’s BiCE platform to DC candidate selection in 2025.”

Janine Schuurman, PhD, newly appointed Board Member of Commit Biologics, said: “Commit’s BiCE platform, which has the potential to give antibody therapeutics the power to strongly activate the complement system, is an extremely exciting technology. I look forward to helping Commit advance BiCE from platform to pipeline, using all the scientific and operational experience I have gained over the years I have been successfully developing antibody-based drugs.”

Dr Schuurman holds a PhD in molecular immunology from the University of Amsterdam.

Commit Biologics is advancing development of its Bispecific Complement Engaging (BiCE™) technology, which is designed to potently activate the complement system – a part of the immune system which has often been overlooked in terms of its therapeutic potential. BiCE uses single domain antibodies that bind to the complement protein C1q, thus directing the complement system in a highly selective way against tumor cells or cells implicated in autoimmune disease.

Dr Schuurman, who previously served as a scientific advisor to Commit, joins its Board of Directors with immediate effect.